Edition:
United Kingdom

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

2.20USD
23 Apr 2018
Change (% chg)

$-0.05 (-2.22%)
Prev Close
$2.25
Open
$2.24
Day's High
$2.25
Day's Low
$2.14
Volume
9,762
Avg. Vol
67,693
52-wk High
$4.54
52-wk Low
$1.35

Select another date:

Tue, Mar 27 2018

BRIEF-Imprimis Pharmaceuticals Issued Composition Patent For Non-Opioid Conscious Sedation Formulation

* IMPRIMIS PHARMACEUTICALS ISSUED COMPOSITION PATENT FOR NON-OPIOID CONSCIOUS SEDATION FORMULATION

BRIEF-Imprimis Pharmaceuticals Q4 Revenue $7.3 Million

* IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS

BRIEF-Imprimis Pharma Makes Available Two Glaucoma Drugs On FDA's Drug Shortage List

* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:

BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Select another date: